Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.

Kyaw Z Thein,Sarina A Piha-Paul,Aung Naing,Siqing Fu,Rivka R Colen,Selma Sulovic,Filip Janku,Daniel D Karp,Apostolia M Tsimberidou,Jing Gong,Lacey Mcquinn,Denái R Milton,Bettzy A Stephen,Jatin Shah,Funda Meric-Bernstam,Brett W Carter

doi:10.36401/jipo-21-20

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.

Kyaw Z Thein, Sarina A Piha-Paul + Show 14 more

Open Access

PDF Available

https://doi.org/10.36401/jipo-21-20

Copy DOI

Export

Save

Cite

Journal: Journal of immunotherapy and precision oncology	Publication Date: Feb 1, 2022
License type: CC BY-NC-ND 4.0

Affiliation: The University of Texas MD Anderson Cancer Center, Karyopharm Therapeutics (United States)

#Common Treatment-related Adverse Event #Selinexor In Combination #Metastatic Solid Tumors #Treatment-related Adverse Event #Cervical Cancer #Hematologic Laboratory Abnormalities #Prior Lines Of Therapies #Treatment-emergent Adverse Events #Carboplatin And Paclitaxel #Dose Of Selinexor

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of immunotherapy and precision oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.